A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
Recruiting
Phase 3
Interventional Study
Clostridioides Difficile Associated Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 65 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 32,000 (estimated)
- Sponsor
- Pfizer · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older.
The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Who Can Join the Study (Inclusion Criteria):
• People with recent or future planned contact with healthcare systems or who have recently received antibiotics.
Who Cannot Join the Study (Exclusion Criteria):
* Anyone who has had CDI before.
* Anyone who has had surgery to remove part of their smal…
Contacts